Experimental Study Shows Increased Survival of Prostate Cancer Patients Using Frozen Immune Cells


Research presented at the annual meeting of the American Society of Clinical Oncology in Chicago on June 4 concluded that metastatic prostate cancer patients who received a vaccine made from their own frozen immune cells lived up to 10 months longer than those who did not receive this intervention. In this exploratory study immune cells (APC8015F) are taken from prostate cancer patients before the disease progresses and frozen. Results showed that following progression, those treated with APC8015F had a median survival rate of 20 months compared to 9.8 months for those not treated with APC8015F. Further research is planned.

Tags: , , ,

Comments are closed.